Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6
Sign Up to like & getrecommendations! Published in 2019 at "Archives of Toxicology"
DOI: 10.1007/s00204-019-02513-7
Abstract: A common strategy to overcome acquired chemotherapy resistance is the combination of a specific anticancer drug (e.g., topoisomerase I inhibitor irinotecan) together with a putative sensitizer. The purpose of this study was to analyze the… read more here.
Keywords: cells irinotecan; bv6; p53; mismatch repair ... See more keywords
Regulation of the antiapoptotic protein cFLIP by the glucocorticoid Dexamethasone in ALL cells
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.24782
Abstract: We recently reported that the Smac mimetic BV6 and glucocorticoids, e.g. Dexamethasone (Dexa), synergize to induce cell death in acute lymphoblastic leukemia (ALL) in vitro and in vivo. Here, we discover that this synergism involves… read more here.
Keywords: protein; dexa; cell death; bv6 ... See more keywords
SMAC Mimetic BV6 Co-Treatment Downregulates the Factors Involved in Resistance and Relapse of Cancer: IAPs and Autophagy
Sign Up to like & getrecommendations! Published in 2022 at "Biology"
DOI: 10.3390/biology11111581
Abstract: Simple Summary Breast cancer is the most prominent cancer among women. Therapeutic resistance and reoccurrence of cancer after various therapies, such as chemotherapy, radiotherapy etc., is the major cause of death. In various studies, it… read more here.
Keywords: cancer; death; bv6; resistance ... See more keywords